Sabin’s diverse partnerships are important to achieving the organization’s mission. The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) leverages the expertise of partners in the academic, public and private sectors and promotes open-source research that focuses on capacity building, infrastructure development and knowledge sharing. To advance product development, we are working with institutions in Europe, Brazil, Malaysia and Mexico to expand product development and manufacturing capabilities to develop new vaccines.
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.
The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new co
2011 Annual Report
September 11, 2012
On behalf of the trustees, management and staff of the Sabin Vaccine Institute, we are pleased to share our most significant accomplishments from the past year in our 2011 annual report.
The Sabin PDP has initiated development for a new therapeutic vaccine for Chagas disease that will be undertaken with partners in Mexico, where between two and six million people are infected with this leading cause of poverty in Latin America. Current efforts focus on the development of two vaccine candidate antigens that will ultimately comprise the first therapeutic vaccine for Chagas disease. The vaccine is being developed in partnership with Baylor College of Medicine and Texas Children’s Hospital.
The Sabin Vaccine Institute PDP works on developing vaccines for the estimated 440 million people suffering from hookworm in the world today. Established in 2000 with funding from the Bill & Melinda Gates Foundation, the Sabin PDP (originally the Human Hookworm Vaccine Initiative) is the first and only PDP in the world developing a vaccine for human hookworm infection.
The Human Hookworm Vaccine Prospectus
The Sabin PDP is focused on the development of sustainable and cost-effective vaccines for preventing widespread neglected tropical diseases (NTDs), including hookworm, schistosomiasis, Chagas disease and leishmaniasis.
July 18, 2012
Last Friday, Sabin president Dr. Peter Hotez was a featured guest on Soledad O’Brien’s CNN morning show “Starting Point.” On the show, Dr. Hotez discussed the burden of neglected tropical diseases (NTDs) globally and closer to home in the United States.